TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of diabetic macular edema.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham
C: Intervention Type: DRUG; Name: Triamcinolone acetate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laser therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: intravitreous triamcinolone | Intervention Type: DRUG; Name: intravitreous triamcinolone; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: laser therapy; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a 60 week study including a double-blind phase followed by an open-label phase.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fremanezumab 675 mg/placebo/placebo; Type: EXPERIMENTAL; Interventions: Drug: Fremanezumab, Drug: Placebo | Arm Label: Fremanezumab 675/225/225 mg; Type: EXPERIMENTAL; Interventions: Drug: Fremanezumab | Intervention Type: DRUG; Name: Fremanezumab; Assigned to Arm(s): Fremanezumab 675 mg/placebo/placebo, Fremanezumab 675/225/225 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fremanezumab 675 mg/placebo/placebo, Placebo
B: Arm Label: botulinum toxin Type A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo (saline) | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): botulinum toxin Type A | Intervention Type: OTHER; Name: placebo (saline); Assigned to Arm(s): Placebo (saline)
C: Intervention Type: DRUG; Name: Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection; Assigned to Arm(s): N/A
D: Arm Label: botulinum toxin Type A; Type: EXPERIMENTAL; Interventions: Biological: Botulinum Toxin Type A | Arm Label: Placebo (saline); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: Botulinum Toxin Type A; Assigned to Arm(s): botulinum toxin Type A | Intervention Type: OTHER; Name: Placebo (saline); Assigned to Arm(s): Placebo (saline)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?
Brief Summary: Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus Vaccine (ROTARIX) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus Vaccine (ROTARIX); Assigned to Arm(s): 1
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?
Brief Summary: Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?
Brief Summary: Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
D: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?
Brief Summary: Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Arm Label: Low birth-weight cohort; Type: N/A; Interventions: N/A
C: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
D: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau
Brief Summary: In the present study the investigators wish to address the effects of different doses of vitamin A supplementation in low and normal birth weight infants.

Hypotheses:

* Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in both normal and low birth weight infants.
* A lower dose of vitamin A may be even more beneficial than a high dose.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): Placebo, Vitamin A
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau
Brief Summary: In the present study the investigators wish to address the effects of different doses of vitamin A supplementation in low and normal birth weight infants.

Hypotheses:

* Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in both normal and low birth weight infants.
* A lower dose of vitamin A may be even more beneficial than a high dose.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
B: Arm Label: Low birth-weight cohort; Type: N/A; Interventions: N/A
C: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Different Doses of Vitamin A Supplementation on Male and Female Childhood Morbidity and Mortality
Brief Summary: We previously compared the effect on mortality of the half dose and the full dose currently recommended by WHO. Unexpectedly, the low dose was clearly better for girls, but not for boys. The girls' response might have depended on the last vaccine received before the OPV and VAS campaign. We believe that these findings call for confirmation. In connection with a new campaign, we will examine whether half the dose or the full dose has a more beneficial effect on mortality and morbidity in girls, and furthermore address the potential effect modification by the last vaccine received before the supplementation.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: vitamin A supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin A supplements | Intervention Type: DRUG; Name: vitamin A supplements; Assigned to Arm(s): vitamin A supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Different Doses of Vitamin A Supplementation on Male and Female Childhood Morbidity and Mortality
Brief Summary: We previously compared the effect on mortality of the half dose and the full dose currently recommended by WHO. Unexpectedly, the low dose was clearly better for girls, but not for boys. The girls' response might have depended on the last vaccine received before the OPV and VAS campaign. We believe that these findings call for confirmation. In connection with a new campaign, we will examine whether half the dose or the full dose has a more beneficial effect on mortality and morbidity in girls, and furthermore address the potential effect modification by the last vaccine received before the supplementation.


Options:
A: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): N/A
B: Arm Label: a; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: b; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: c; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: d; Type: PLACEBO_COMPARATOR; Interventions: Drug: glycine | Arm Label: e; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A, Drug: zinc | Arm Label: f; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A, Drug: zinc | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): a | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): b, c, e, f | Intervention Type: DRUG; Name: glycine; Assigned to Arm(s): d | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): b, c, e, f
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: Determine the efficacy, safety, and tolerability of BG00012 in MS patients.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
C: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: Determine the efficacy, safety, and tolerability of BG00012 in MS patients.


Options:
A: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon-beta-1a (Avonex) plus methylprednisolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon-beta-1a (Avonex) plus methylprednisolone | Intervention Type: DRUG; Name: Interferon-beta-1a (Avonex) plus methylprednisolone; Assigned to Arm(s): 1, 2
D: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: Determine the efficacy, safety, and tolerability of BG00012 in MS patients.


Options:
A: Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
C: Arm Label: BAF312 10mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 0.5 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 to 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 - 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo (period 1, 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 0.5 mg (period 1), BAF312 10mg (period 1), BAF312 2 mg (period 1), BAF312 dose between 0.1 - 8 mg period 2, BAF312 dose between 0.1 to 8 mg period 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (period 1, 2)
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: A